Our advantages and services that will satisfy you:
News
On October 24, the US Food and Drug Administration (FDA) approved the launch of the new anti-influenza drug Xofluza (baloxavir marboxil), jointly developed by Japan’s Yanyeyi Pharmaceutical Co. and Roche, for the treatment of 12-year-old and above without complications. Acute flu patients. It is worth mentioning that this is the new anti-viral flu treatment method approved by the FDA for the first…
Talazoparib is a once-a-day oral poly ADP ribose polymerase (PARP) inhibitor. Preclinical studies have shown that talazoparib has a strong activity and has a dual mechanism of action, which can induce tumor cell death by blocking PARP enzyme activity and capturing PARP at the site of DNA damage. Talazoparib is currently being evaluated for advanced gBRCAm breast cancer, early triple-negative breas…
On October 8th, Akcea and Ionis' Tegsedi were approved by the US FDA for hereditary parathyroid hormone amyloidosis (HATTR), a rare disease that forms starch in the peripheral nervous system and multiple organs. Protein accumulation. Tegsedi (inotersen) is designed to block the production of TTR proteins, and the slow accumulation of TTR proteins causes sensory, motor and autonomic dysfunction in…
Elapegademase-lvlr is a novel enzyme replacement therapy for the treatment of adenosine deaminase deficiency in severe combined immunodeficiency (ADA-SCID) in children and adults. (ADA-SCID is an ultra-rare and highly destructive hereditary disease. Patients affected by ADA-SCID have an impaired immune system that prevents patients from fighting bacterial, viral and fungal infections.)
Revcovi is…
Omadacycline is a new generation of aminomethylcyclotetracycline developed by Paratek Pharmaceuticals, which has a broad spectrum of activity against Gram-positive, Gram-negative and atypical bacteria.
Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline…
Paratek Pharmaceuticals announced on October 2 that the FDA approved Seysara (sarecycline) for the treatment of moderate to severe acne in people over 9 years of age.
Sarecycline is a once-a-day, oral, narrow-spectrum tetracycline-derived antibiotic with anti-inflammatory properties that can be used as a potential treatment for moderate to severe acne in a community setting.
Paratek is a biophar…
September 28, 2018, The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.
Libtayo works by t…
Lung cancer is one of the most common malignant tumors and the first cause of death in malignant tumors in urban population in China. Non-small cell lung cancer accounts for 80% of lung cancer. EGFR is a protein that helps cells grow and divide. When it is mutated, it can cause cancer cells to form. EGFR mutations occur in 10% to 35% of non-small cell lung cancer worldwide.
In April of this year,…
The US FDA has approved Verastem's new anticancer drug Duvelisib (Copiktra) for the treatment of adults who have undergone at least two previous treatments, relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Duvelisib also received accelerated approval for treatment of adult patients with relapsed or refractory follicular lymphoma.
Duvelisib (IPI-145), a novel oral…
Galcanezumab-gnlm (Emgality™; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand. A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis. In September 2018, the US FDA approved galcanezumab as a once-monthly subcutaneous injection for the preventive treatment of migrain…
Fremanezumab-vfrm (hereafter referred to as fremanezumab) [AJOVY™] is a fully humanized monoclonal antibody (IgG2Δa) developed by Teva Pharmaceuticals to selectively target calcitonin gene-related peptide (a vasodilatory neuropeptide involved in the pathophysiology of migraine). Its use has been associated with significant reductions in migraine frequency, the requirement for acute headache medica…
September 13, 2018, The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first of t…